A month-by-month analysis of direct oral anticoagulants for secondary prevention of acute coronary syndrome

Abstract

Get full access to this article

View all access options for this article.

References

Chiarito

Cao

Cannata

et al.

Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: A systematic review and meta-analysis. JAMA Cardiol 2018; 3: 234–241.

Mega

Braunwald

Mohanavelu

et al.

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009; 374: 29–38.

Alexander

Lopes

James

et al.

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699–708.

Mega

Braunwald

Wiviott

et al.

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9–19.

Wei

Royston

. Reconstructing time-to-event data from published Kaplan–Meier curves. Stata J 2017; 4: 786–802.

Lettino

Leonardi

De Maria

et al.

Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. Eur J Prev Cardiol 2017; 24: 61–70.